The European Medicine Agency (EMA), the major medical regulator of the European Union, announced on Tuesday that it started reviewing an experimental Spanish COVID-19 vaccine booster made, Hipra.
EMA said in its statement that its evaluation for the new booster is based on data from the study laps and research centres that compare the results of Hipra to a booster made by Pfizer-BioNTech.
The early data showed that Hipra's booster is effective and it has an effective immune response against COVID-19, including the Omicron variant.
Hipra, the Spanish booster, is a protein-based vaccine it uses the same technology as Novavax that was approved by EMA last December.
It consisted of two Coronavirus spike proteins that were adjusted at the lab to enhance the immune response of the person.
The booster will be used for RNA technology-based vaccines, AstraZeneca, and Johnson & Johnson.
It can also be used in the strategy of mix-match vaccine methodology.
Follow the latest news on Google News
